Related references
Note: Only part of the references are listed.Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model
Anu Shilpa Krishnatry et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
Sarina A. Piha-Paul et al.
JNCI CANCER SPECTRUM (2020)
Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
Gloria Manzotti et al.
CANCERS (2019)
Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition
Matthew L. Hemming et al.
CANCER RESEARCH (2019)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers
Anastasia Wyce et al.
ONCOGENESIS (2018)
Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762
Di Zhang et al.
CANCER PREVENTION RESEARCH (2018)
HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
Xiaoyu Lin et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Salmon provides fast and bias-aware quantification of transcript expression
Rob Patro et al.
NATURE METHODS (2017)
BET inhibitors as novel therapeutic agents in breast cancer
Alberto Ocana et al.
ONCOTARGET (2017)
Targeting Cancer Cells with BET Bromodomain Inhibitors
Yali Xu et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Measure transcript integrity using RNA-seq data
Liguo Wang et al.
BMC BIOINFORMATICS (2016)
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
Anastasios Stathis et al.
CANCER DISCOVERY (2016)
Platelet Transfusion: A Clinical Practice Guideline From the AABB
Richard M. Kaufman et al.
ANNALS OF INTERNAL MEDICINE (2015)
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
Timothy J. Stuhlmiller et al.
CELL REPORTS (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma
A. R. Grayson et al.
ONCOGENE (2014)
NSD3-NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
Christopher A. French et al.
CANCER DISCOVERY (2014)
MYC Activation Is a Hallmark of Cancer Initiation and Maintenance
Meital Gabay et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Anastasia Wyce et al.
ONCOTARGET (2013)
RSeQC: quality control of RNA-seq experiments
Liguo Wang et al.
BIOINFORMATICS (2012)
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Panagis Filippakopoulos et al.
CELL (2012)
Molecular signatures database (MSigDB) 3.0
Arthur Liberzon et al.
BIOINFORMATICS (2011)
Bromodomains as therapeutic targets
Susanne Muller et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2011)
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription
Anup Dey et al.
MOLECULAR BIOLOGY OF THE CELL (2009)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells
C. A. French et al.
ONCOGENE (2008)
Brd4 recruits P-TER to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression
Zhiyuan Yang et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Structure and acetyl-lysine recognition of the bromodomain
S. Mujtaba et al.
ONCOGENE (2007)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Midline carcinoma of children and young adults with NUT rearrangement
CA French et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
